Pfizers BBC Ghosts, Gileads NASH, HLIs Cash
Summary
The newly un-betrothed Allergan has wasted no time, announcing late Wednesday a licensing deal for experimental neurological treatments with British firm Heptares Therapeutics.—Gilead Sciences (NASDAQ: GILD) of Foster City, CA, augmented its pipeline of experimental drugs to fight the fatty liver disease known as NASH with a $400 million deal.In the meantime, Gilead’s NASH rival Intercept Pharmaceuticals (NASDAQ: ICPT) is hearing from FDA advisors this week about its drug obeticholic acid (OCA), which the agency is considering as a treatment for a rare form of liver disease caused by autoimmune attack.STAT also says it’s not clear whether volunteers recruited to Baseline have been told that their data could be packaged and sold to third parties, such as pharmaceutical companies looking for clues to help with drug development.When Pfizer’s San Francisco biotech center fell apart and Corey Goodman left, he kept an eye on the drug, then extracted it years later to form a company around it.